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Abl interactor (Abi) 1 was ﬁrst identiﬁed as the downstream tar-
get of Abl tyrosine kinases and was found to be dysregulated in
leukemic cells expressing oncogenic Bcr-Abl and v-Abl. Although
the accumulating evidence supports a role of Abi1 in actin cyto-
skeleton remodeling and growth factor/receptor signaling, it is not
clear how it contributes to Bcr-Abl-induced leukemogenesis. We
show here that Abi1 gene silencing by short hairpin RNA atten-
uated the Bcr-Abl-induced abnormal actinremodeling, membrane-
type 1 metalloproteinase clustering and inhibited cell adhesion
and migration on ﬁbronectin-coated surfaces. Although the knock
down of Abi1 expression did not affect growth factor-independent
growth of Bcr-Abl-transformed Ba/F3 cells in vitro, it impeded
competitive expansion of these cells in non obese diabetic
(NOD)/ severe combined immuno-deﬁciency (SCID) mice.
Remarkably, the knock down of Abi1 expression in Bcr-Abl-
transformed Ba/F3 cells impaired the leukemogenic potential of
these cells in NOD/SCID mice. Abi1 contributes to Bcr-Abl-
induced leukemogenesis in part through Src family kinases, as
the knock down of Abi1 expression attenuates Bcr-Abl-stimulated
activation of Lyn. Together, these data provide for the ﬁrst time
the direct evidence that supports a critical role of Abi1 pathway in
the pathogenesis of Bcr-Abl-induced leukemia.
Introduction
More than 95% of human chronic myelogenous leukemia and a subset
of acute lymphocytic leukemia are caused by expression of Bcr-Abl,
a fusion oncogene generated by reciprocal t(9;22)(q34;q11) chromo-
some translocation (1–3). Bcr-Abl-positive leukemias are character-
ized by premature release of myeloid and lymphoid lineage cells from
bone marrow, followed by the expansion of these cells in peripheral
blood and inﬁltration of organs such as spleen, liver and lung (1,3).
The progression of these diseases involves not only accelerated cell
proliferation and enhanced cell survival but also increased cell motil-
ity and active invasion of leukemic cells through blood vessel and
matrix barriers (4,5). Although numerous studies have revealed that
Bcr-Abl may activate multiple signaling pathways that are involved in
cytoskeletal functions (4–14), precise mechanisms by which Bcr-Abl
induces abnormal cytoskeletal functions in leukemic cells are not
completely understood.
Bcr-Abl oncoproteins exert their oncogenic potential in coopera-
tion with additional cytoplasmic and nuclear effectors such as those
involved in the regulation of mitogenic and apoptotic pathways. They
are also capable of binding to cytoskeleton proteins as well as the
proteins involved in the regulation of cell adhesion and migration
(4,5,10). Among these proteins is Abl interactor (Abi) (15,16), a key
regulator of Rac-dependent actin polymerization (17,18). Mammalian
Abi proteins consist of three members: Abi1 (also known as e3b1),
Abi2 and Abi3 (also known as new molecule including SH3)
(15,16,19). These proteins are present in cells as a complex with
WASP-family verprolin-homologous (WAVE) proteins,Nck-associated
protein, speciﬁcally Rac-associated protein, and hematopoietic stem
progenitor cell 300 (17,20–22). The micromolecular complex (Abi–
WAVE complex) regulates initiation of actin polymerization in re-
sponse to Rac activation. In addition to the interactions with Abl,
WAVE and Nck-associated protein, Abi proteins were also found to
interact with a variety of other signaling molecules that are involved in
the control of cell proliferation, apoptosis and cytoskeletal functions
(23–37). Accumulating evidence suggests that Abi proteins may be
involved in the signal transduction from membrane receptors to small
guanosine triphosphate (GTP)-binding proteins and phosphoinositide
3-kinase (PI3 kinase) as well (26,27,36).
In hematopoietic cells transformed by Bcr-Abl, Abi1 is tyrosine
phosphorylated and Abi2 is degraded (38,39). Recent studies have
shown that Abi1 plays a critical role in Bcr-Abl-induced remodeling
of actin cytoskeleton as well as clustering of adhesion molecules and
membrane-type 1 metalloproteinase (MT1-MMP) (40,41). Blockade
of the signal transduction from Bcr-Abl to Abi1 appeared to impair
Bcr-Abl-stimulated cell adhesion and migration in vitro (40).
Although these studies provide evidence in support of the role of
Abi1 in Bcr-Abl transformation, it is not clear how and whether
Abi1 contributes to Bcr-Abl-induced leukemogenesis in vivo. In pres-
ent studies, we show that silencing the Abi1 gene by sequence-
speciﬁc short hairpin RNA (shRNA) inhibited Bcr-Abl-stimulated
cell adhesion and migration. Notably, the knock down of Abi1 ex-
pression impaired Bcr-Abl-induced leukemogenesis in vivo, possibly
by impeding leukemic cell expansion and homing.
Materials and methods
Cell lines and reagents
Ba/F3 cells weregrown in RPMI containing10% fetal bovine serum (FBS) and
15% WEHI3-conditioned medium as a source of IL3. The Ba/F3 cell lines
expressing wild-type p185Bcr-Abl (p185wt) or expressing both p185wt and Abi1
shRNAwere cultured in RPMI containing 10% FBS. Retroviral packaging cell
line GP2-293 (ClonTech, Mountain View, CA) was grown in Dulbecco’s mod-
iﬁed Eagle’s medium containing 10% FBS. The preparation of rabbit poly-
clonal antibodiesagainstAbi1 and Abi2has beendescribed previously(38,42).
The antibodies against WAVE2, Lyn and phosphotyrosine-containing proteins
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and the
monoclonal antibodies for Abl were obtained from BD PharMingen (San Die-
go, CA). The antibody against phospho-Src family (Tyr 416) (including phos-
pho-Lyn kinase) was purchased from Cell Signaling Technology (Danvers,
MA). The monoclonal anti-b-actin antibody and the protease inhibitor cocktail
were purchased from Sigma (St Louis, MO). The recombinant rat IL3 was
purchased from PeproTech (Rocky Hill, NJ).
Plasmids and retroviral infection
Transfection of Ba/F3 cells with pSRap185wt was described previously (38).
Three murine stem cell virus-based pSM2 retroviral vectors containing
Abbreviations: Abi, Abl interactor; F-actin, ﬁlament actin; FBS, fetal bovine
serum; MT1-MMP, membrane-type 1 metalloproteinase; PBS, phosphate-
buffered saline; PCR, polymerase chain reaction; shRNA, short hairpin
RNA; WAVE, WASP-family verprolin-homologous.
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vector encoding non-silencing shRNA, were purchased from Open Biosystems
(Huntsville, AL). The sequences in Abi1 that are targeted by three shRNAs are
as follows—shRNA A: ATGTCTACCTGTAAGCATA; shRNA B: CTCGAA-
GAGAGATTGGTAT and shRNA C: GTGCAATCATCTATGTTAT. The
expression of shRNAwas driven by U6 promoter. Ampliﬁcation and puriﬁca-
tion of plasmid DNA were performed as speciﬁed by the manufacturer’s in-
struction. MSCV-green ﬂuorescence protein (GFP) retroviral vector expressing
enhanced green ﬂuorescence protein was generated by subcloning an EcoR1/
Not1 complementary DNA fragment encoding for enhanced green ﬂuores-
cence protein into MSCV vector. Preparation of retroviruses and infection of
Ba/F3and Ba/F3p185wt celllineswereperformedasdescribedpreviously(39).
Stable cell lines were selected by addition of puromycin into media (2 lg/ml).
Biochemical assays
Quantitative real-time reverse transcription–polymerase chain reaction (PCR)
was performed on MyiQ single-color real-time PCR detection system (Bio-
Rad, Hercules, CA) using mouse Abi1 primers (forward: 5#-AATCGCACC-
CGCAAATATG-3# and reverse: 5#-GTTCTCGACAATGTGCCAGTTC-3#)
combined with SYBR Green Master Mix (Applied Biosystems, Foster City,
CA). Brieﬂy, total RNA was extracted from cells using RNeasy mini kit
(Qiagen, Valencia, CA) and complementary DNAwas subsequently generated
using SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad,
CA). The PCRs began with 10 min at 95C for AmpliTaq Gold activation
followed by 40 cycles at 95C for 15 s for denaturation then 60C for 1 min
for annealing/extension. Relative quantiﬁcation was done using glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) (forward primer: 5#-AACGAC-
CCCTTCATTGAC-3#andreverseprimer:5#-TCCACGACATACTCAGCAC-3#)
as an endogenous control.
Immunoprecipitation and western blot analyses were performed as de-
scribed previously (40). Brieﬂy, control Ba/F3 cells and the Ba/F3 cells ex-
pressing p185wt and p185wt plus Abi1 shRNA were lysed in lysis buffer
(20 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid, pH 7.2, 150 mM
NaCl, 1% Triton X-100 and 10% glycerol) and incubated with appropriate
antibodies bound to Sepharose beads. The immunoprecipitates were separated
on sodium dodecyl sulfate–polyacrylamide gel electrophoresis, transferred to
nitrocellulose and immunoblotted with appropriate antibodies.
In vivo leukemogenesis studies
A suspension of 1   106 Ba/F3 cells or Ba/F3 cells expressing p185wt alone or
p185wt plus Abi1 shRNA was injected into 6- to 8-week-old female NOD/
SCID mice through tail vein. The mice were followed for disease development
as judgedby symptoms such asabnormal gaitand laboredbreathing. Moribund
animals were killed by CO2 asphyxiation and were examined for tumors or
other visible abnormalities. Collection of spleens, livers and bone marrow cells
was performed immediately after killing. All protocols used were approved by
Institutional Animal Review Committee at the Texas Tech University Health
Sciences Center.
To examine the capacity of in vivo competitive expansion, the Ba/F3p185wt
cells transduced with MSCV-based retroviruses expressing either GFP or Abi1
shRNAwere mixed in vitro at 1:1 ratio and then injected into mice through tail
vein. The Ba/F3-derived leukemic cells were rescued from peripheral blood,
spleens and bone marrow of the diseased mice by culturing them in RPMI
containing 10% FBS for 2–7 days under selection with puromycin.
Adhesion and migration assays
For adhesion assay, Ba/F3 cells and Ba/F3 cells expressing either p185wt alone
or p185wt plus Abi1 shRNA were plated in six-well plates (2.5 ml per well)
coated with ﬁbronectin (BD Biosciences, Bedford, MA) and incubated at
37C/5% CO2 for 16 h. Non-adherent cells were removed and adherent cells
were washed three times with 1 ml prewarmed RPMI medium. The adherent
cells thenwere trypsinizedand collected. Both non-adherentand adherent cells
were counted to determine the percentage of adherent cells.
The cell migration assay was performed as described previously (39). The
inserts of Transwell plates (8 lm pores, Corning Costar Corp., Cambridge,
MA) were coated with human ﬁbronectin (Sigma). The control Ba/F3 cells and
the Ba/F3 cells expressing p185wt alone or pl85wt plus Abi1 shRNA were
resuspendedinRPMIcontaining0.1%bovineserumalbuminataconcentration
of1 106 cells/ml. A suspension of 0.1 ml cells was added into ﬁbronectin-coated
insert and cells were allowed to migrate at 37Ci n5 %C O 2 incubator for 6–8 h.
Fluorescence microscopy and ﬂow cytometry analysis
Cultured Ba/F3 cell lines were ﬁxed in 4% paraformaldehyde in phosphate-
buffered saline (PBS) for 10 min, permeabilized in 0.2% Triton X-100/PBS for
5 min and stained with 50 lg/ml tetramethyl rhodamine iso-thiocyanate
(TRITC)-conjugated phalloidin (Sigma) in PBS. After washing extensively
with PBS and a brief staining with 4#,6-diamidino-2-phenylindole (Sigma)
to visualize nuclei, 5–10   103 cells were loaded per slide by cytospin and
mounted with Vectashield mounting medium (Vector, Burlingame, CA). Im-
ages werecaptured and analyzedusing NikonTE-2000microscopewithImage
software associated. For ﬂuorescence-activated cell sorting of GFP-positive
cells, Ba/F3 cells transfected with p185wt and MSCV-GFP were resuspended
in PBS and subjected to ﬂow cytometry (FACS Calibur Flow Cytometer, BD
Biosciences) analysis using the software associated. GFP-positive cells were
collected with .95% purity. These cells were grown in vitro and used for in
vivo competitive expansion assay. To determine the percentage of GFP-positive
cells in those cells rescued from diseased mice, rescued cells were grown in
puromycin selection media for 2–7 days to morphologically homogenous. The
cellswerecollected,washedandresuspendedinPBSforﬂowcytometryanalysis.
Statistical analysis
Descriptive statistics were generated for all quantitative data with the presen-
tation of means ± SDs. Signiﬁcance of comparisons between experimental
groups was tested using the Student’s t-test.
Results
ShRNA-induced Abi1 gene silencing in Bcr-Abl-transformed Ba/F3
cells
We have shown previously that Abi1 is tyrosine phosphorylated in he-
matopoieticcellstransformedbyBcr-Abl(39).TotesttheroleofAbi1in
Bcr-Abl-induced cellular transformation and leukemogenesis, shRNAs
with either scrambled sequences or the sequences that speciﬁcally target
different regions of Abi1 transcript were introduced into p185Bcr-Abl-
transformed Ba/F3 cells (p185wt cells) by retroviral transduction. Stable
cell populations were selected by puromycin and tested for the effect of
shRNA on Abi1 expression. Remarkably, the expression of Abi1 in
p185wt cells transduced with Abi1 shRNA was reduced to a level un-
detectablebywesternblotanalysis,ascomparedwithp185wt cellstrans-
duced with scrambled shRNA (Figure 1A, compare lanes 3–5 with lane
2). To compare the efﬁcacy of the Abi1 knockdownby different shRNA,
quantitative real-time PCR analysis was performed. As shown in Figure
1B (lower panel), expression of Abi1 shRNAs B and C in p185wt cells
resulted in a decrease of Abi1 messenger RNA level by 95 and 90%,
respectively, as compared with the p185wt cells expressing scrambled
shRNA (p185wt control cells). Consistently, immunoprecipitation fol-
lowed by western blot analysis using Abi1-speciﬁc antibody revealed
that among three shRNA constructs tested, shRNA A induces  70%
reduction of Abi1 protein level, whereas the shRNAs B and C caused
.90% reduction of Abi1. The p185wt Abi1 shRNA B and C cells
(p185wt Abi1 shRNA cells), therefore, were chosen for further studies.
The expression of Bcr-Abl in hematopoietic cells induces down-
regulation of Abi2 (38). To determine if Abi1 knockdown affects the
Bcr-Abl-induced Abi2 downregulation, we examined the protein level
of Abi2 in p185wt Abi1 shRNA cells. Consistent with the previous
report (38), the expression of Abi2 is lost in p185wt control cells as
compared with Ba/F3 cells (Figure 1C). Similarly, no Abi2 was de-
tected in p185wt Abi1 shRNA cells (Figure 1C), suggesting that Bcr-
Abl-induced downregulation of Abi2 is not affected by Abi1 knock-
down. We also examined the protein level of WAVE2 in p185wt Abi1
shRNA cells. In line with the results reported by other investigators
(18,20,43), the knock down of Abi1 in p185wt cells resulted in a re-
duction of WAVE2 protein level (Figure 1C).
Abi1 knockdown does not affect Bcr-Abl-induced protein tyrosine
phosphorylation and IL3-independent growth of Ba/F3 cells
Abi proteins have been shown capable of regulating the tyrosine kinase
activityofcAbl(44,45). To determine if the Abi1 knockdown affects the
tyrosine kinase activity of Bcr-Abl, we examined the tyrosine phosphor-
ylation proﬁle of the p185wt Abi1 shRNA cells. Expression of p185wt in
Ba/F3 cells resulted in elevated protein tyrosine phosphorylation, as
compared with parental Ba/F3 cells (Figure 2A). It appeared that Abi1
knockdown had little, if any, effect on Bcr-Abl-induced protein tyrosine
phosphorylation (Figure 2A, compare lane 3 with lanes 1 and 2).
Next, we tested if the Abi1 knockdown affects Bcr-Abl-induced
IL3-independent growth of Ba/F3 cells. The Ba/F3, p185wt control
and p185wt Abi1 shRNA cells were grown in RPMI 1640 media
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1718containing 10% FBS with no addition of IL3. Unlike parental Ba/F3
cells, which failed to grow and died within 72 h in IL3-free medium
(Figure 2B), the p185wt controlcells and the p185wt Abi1 shRNA cells
grew equally well in this medium. Thus, the knock down of Abi1
expression had no effect on Bcr-Abl-induced IL3-independent growth
of Ba/F3 cells.
Abi1 knockdown inhibits Bcr-Abl-stimulated abnormal cytoskeleton
remodeling, MT1-MMP clustering, as well as cell adhesion and
migration
Given that Abi1 is a keyregulator of actin polymerization, we tested if
the Abi1 knockdown affects Bcr-Abl-induced abnormal cytoskeletal
functions, such as abnormal actin cytoskeleton remodeling, cell ad-
hesion and migration. Expression of p185wt in Ba/F3 cells induced
a profound actin cytoskeleton remodeling. Speciﬁcally, a spot inten-
sively stained by phalloidin, indicative of ﬁlament actin (F-actin)
aggregates, was observed in p185wt cells, but not in Ba/F3 cells and
the Ba/F3 cells transfected by a construct expressing a kinase-deﬁ-
cient Bcr-Abl (p185K671R, Figure 3A). Expression of Abi1 shRNA in
p185wt cells resulted in a 3-fold reduction in the formation of abnor-
mal F-actin-enriched structures (Figure 3A).
In previous studies, we have shown that MT1-MMP, a member of
transmembrane metalloproteinases that is responsible for the degra-
dation of a variety of extracellular matrix, is clustered in Ba/F3 cells
upon Bcr-Abl transformation (41). We therefore tested if the Abi1 is
required for Bcr-Abl-induced clustering of MT1-MMP. We intro-
duced retroviral vectors expressing either control shRNA or Abi1
shRNA into p185wt cells that express GFP-tagged MT1-MMP (41).
Consistent with our previous results (41), GFP-tagged MT1-MMP
displayed a clustered distribution in control p185wt cells (Figure
3B). In contrast, clustering of GFP–MT1-MMP was reduced in
p185wt Abi1 shRNA cells (Figure 3B), suggesting an involvement
of Abi1 in Bcr-Abl-induced clustering of MT1-MMP.
We then tested the effect of Abi1 knockdown on Bcr-Abl-stimulated
cell adhesion and migration. As shown in Figure 3C, expression of
p185wt in Ba/F3 cells stimulated cell adhesion and spontaneous cell
migration on ﬁbronectin-coated surfaces. However, expression of
Abi1 shRNA in p185wt cells inhibited the Bcr-Abl-stimulated cell
adhesion and migration on ﬁbronectin-coated surfaces (Figure 3C).
Together, these results strongly suggest that Abi1 pathway plays an
important role in Bcr-Abl-induced abnormalities of cytoskeletal func-
tions of leukemic cells.
Bcr-Abl-induced leukemogenesis is impaired by Abi1 knockdown
The shRNA-mediated Abi1 knockdown in p185wt Abi1 shRNA cells
is stable. After 5-week culture in vitro, expression of Abi1 remained
undetectable in total lysate of p185wt cells transduced with Abi1
shRNA (Figure 4A). This allowed us to test if Abi1 knockdown af-
fects Bcr-Abl-induced leukemogenesis in vivo. Ba/F3, p185wt control
and p185wt Abi1 shRNA cells were injected intravenously into NOD/
SCID mice through tail vein. The recipient micewere followed for the
Fig. 1. The shRNA-mediated Abi1 gene silencing. (A) Abi1 expression in Ba/F3 cells (BaF3) and p185wt cells transduced with either non-silencing shRNA
(p185wt) or Abi1 shRNAs (shRNAs A, B and C). Total lysates from 1   106 cells were separated on sodium dodecyl sulfate–polyacrylamide gel electrophoresis
and were transferred to nitrocellulose membrane. The membrane was probed with the antibodies as indicated. The p185 Bcr-Abl and c-Abl were indicated by the
arrow and arrowhead, respectively. (B) Efﬁcacy of Abi1 knockdown by different Abi1 shRNAs. The lysates (2   107 cells) from the indicated cell lines were
immunoprecipitated (IP) by Abi1 antibody and the immunoprecipitates were analyzed by western blotting(WB) using Abi1 antibody as probe (upper panel). Total
RNAs from the indicated cell lines were isolated and the complementary DNAs were synthesized. Real-time quantitative PCR (lower panel) was performedt o
determine Abi1 messenger RNA (mRNA) levels, which are expressed as the levels relative to that of GAPDH. Data represent mean ± SD of triplicate experiments;
 P , 0.001. (C) Expression of Abi2 and WAVE2 in Ba/F3 cells and p185wt cells transduced with either non-silencing shRNA or Abi1 shRNAs. Total lysates from
1   106 cells were separated on sodium dodecyl sulfate–polyacrylamide gel electrophoresis and were transferred to nitrocellulose membrane. The membrane was
probed with the antibodies as indicated.
Fig. 2. Abi1 knockdown did not affect Bcr-Abl-induced protein tyrosine
phosphorylation and IL3-independent growth. (A) Proﬁles of protein
tyrosine phosphorylation in Ba/F3 cells and p185wt cells transduced with
either non-silencing shRNA (p185wt) or Abi1 shRNAs (Abi1R). Indicated
cell lines werestarvedin RPMI1640plus0.1% bovine serum albuminfor 6h
prior to harvest. Total lysates from 1   106 cells were separated on 8%
sodium dodecyl sulfate–polyacrylamide gel electrophoresis and subjected to
western blot analysis with anti-phosphotyrosine antibody. (B) IL3-
independent growth of Ba/F3cells as well asthe p185wt cells transducedwith
either non-silencing shRNA (p185wt) or Abi1 shRNA (Abi1R).
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1719development of leukemia. The mice injected with Ba/F3 cells were
healthy with no signs of leukemia for up to 3 months (Table I and
Figure 4B). In contrast, the mice injected with p185wt control cells
developed leukemia in 2–3 weeks. These mice either died or became
moribund (Figure 4B) with a mean latency of 17.5 days (Table I). The
mice injected with p185wt Abi1 shRNA cells survived longer with
a mean latency of 35.8 days (Figure 4B). Gross pathology analysis
revealed that all the mice injected with p185wt control cells developed
splenomegaly and hepatomegaly (Table I and Figure 5A and B),
whereas no apparent splenomegaly or hepatomegaly was observed in
mice injected with p185wt Abi1 shRNA cells (Table I and Figure 5A).
Histopathology analysis showed that the destruction of normal cy-
toarchitecture in the spleen and liver, due to the massive accumulation
of tumor cells, was observed in the mice injected with p185wt control
cells (Figure 5B). In contrast, no apparent abnormality of the splenic
and hepatic cytoarchitecture was observed in the mice injected with
p185wt Abi1 shRNA cells (Figure 5B).
Abi1 knockdown impedes in vivo competitive expansion of Bcr-Abl-
transformed cells
Although the mice received p185wt Abi1 shRNA cells showed longer
survival as compared with those received p185wt control cells, they
eventually developed disease and became moribund  5 weeks after
injection. Because the MSCV vector used for expression of control or
Abi1 shRNA also contains the gene that confers puromycin resis-
tance, we were able to recover the transduced cells from the diseased
mice. The cells capable of growing in IL3-free medium containing
puromycin were readily recovered from the peripheral blood, bone
marrow and spleen of the diseased mice received p185wt control cells.
These cells became predominant in 3–5 days in culture under puro-
mycin selection and displayed the morphology similar to that of the
p185wt control cells grown invitro. Similarly, the puromycin-resistant
cells were readily recovered from the peripheral blood and bone mar-
row of the diseased mice injected with p185wt Abi1 shRNA cells.
With a prolonged culture period (7–10 days), the puromycin-resistant
cells were also recovered from the spleen of some diseased mice
injected with p185wt Abi1 shRNA cells. In contrast, no puromycin-
resistant cells were recovered from the mice injected with control
BaF3 cells.
Fig. 3. Abi1 knockdown inhibited Bcr-Abl-stimulated actin cytoskeleton remodeling, MT1-MMP clustering, as well as cell adhesion and migration on
ﬁbronectin-coated surfaces. (A) Inhibitionof Bcr-Abl-inducedabnormal actin remodelingby Abi1 knockdown. Ba/F3 cells and the Ba/F3 cells expressing p185wt,
p185K671R and p185wt plus Abi1 shRNA were ﬁxed and stained with TRITC-conjugated phalloidin. The cells with F-actin-rich structures (invadopodia-like
structures) were visualized by ﬂuorescence microscopy as shown by arrowheads (upper panel) and were counted (lower panel, represented as mean ± SD
percentage of three randomly picked areas). (B) The p185wt cells expressing GFP–MT1-MMP were transduced with either control retrovirus (control) or the
retrovirus expressing Abi1 shRNA. The knock down of Abi1 expression was conﬁrmed by western blotting (data not shown). The distribution of GFP–MT1-MMP
was visualized by ﬂuorescence microscopy. A similar result has been described previously (41). (C) Effects of Abi1 knockdown on Bcr-Abl-stimulated cell
adhesion(lower panel)and migration(upper panel)on ﬁbronectin-coated surfaces. Ba/F3cells andthe p185wt cells transducedwitheither non-silencing shRNA or
Abi1 shRNAs were grown in ﬁbronectin-coated six-well plate (2.5   105 per well) for 16 h. The total cells and the cells that were adherent to ﬁbronectin-coated
surfaces were counted and the percentage of adherent cells calculated. The vertical axis shows the percentage of the adherent cells and is expressed as the mean ±
SD of triplicate wells. For cell migration on ﬁbronectin-coated membrane, 1   105 cells were tested in Transwell migration assay. The vertical axis shows the
percentage of the migrated cells and is expressed as the mean ± SD of triplicate wells;  P , 0.01.
Fig. 4. Bcr-Abl-induced leukemogenesis was impaired by Abi1 knockdown.
(A) Stable knock down of Abi1 expression in p185wt cells transduced with
Abi1 shRNA. The Ba/F3 cells and the p185wt cells transduced with a non-
silencing shRNA or Abi1 shRNA were grown in vitro for indicated time.
Total lysates from 1   106 cells were separated on sodium dodecyl sulfate–
polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane
and subjected to western blot analysis using indicated antibodies. (B)
Survival of the mice injected with Ba/F3 cells, control p185wt cells and the
p185wt cells expressing Abi1 shRNA.
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1720Western blot analysis was performed to compare the expression of
Abi1, Abi2 and Bcr-Abl among cultured Ba/F3, p185wt control and
p185wt Abi1 shRNA cells, as well as the cells recovered from the
diseased mice. As expected, the puromycin-resistant cells recovered
from the diseased mice express Bcr-Abl (Figure 6A). Expression of
Abi2 was greatly reduced in these cells as compared with cultured Ba/
F3 cells (Figure 6A), possibly due to the Bcr-Abl-induced Abi2 deg-
radation (38). Like p185wt control cells cultured in vitro, the cells
recovered from the diseased p185wt mice expressed Abi1 (Figure
6A). Interestingly, Abi1 was also detected in the cells recovered from
the diseased mice injected withp185wt Abi1 shRNA (Figure 6A). This
is different from the p185wt Abi1 shRNA cells cultured in vitro,i n
which no Abi1 expression was detected even after the cells grew
invitro for.5 weeks (Figures4A and 6A). This result may be explained
by a selective expansion occurred in vivo for those cells that regained
the expression of Abi1. Thus, the data suggest that the Abi1 knock-
down may impede in vivo competitive expansion of the p185wt Abi1
shRNA cells. To test this, we transduced p185wt cells with a retroviral
vector expressing GFP. The GFP-positive p185wt cells (p185wt GFP
cells) were sorted by ﬂuorescence-activated cell sorting to a purity of
.95% (Figure 6B, middle panel in column preinjection). These cells
remain GFP positive after they grew invitro for .30 days (Figure 6B,
middle panel in column in vitro). We mixed p185wt GFP cells with
p185wt Abi1 shRNA cells at 1:1 ratio (Figure 6B, lower panel in
column preinjection) and injected them into recipient mice. We also
injected either the p185wt Abi1 shRNA or p185wt GFP cells alone into
the recipient mice. Thepuromycin-resistant cells were recoveredfrom
the diseased mice and analyzed by ﬂow cytometry. As shown in
Figure 6B, all cells recovered from the mice injected with p185wt
Abi1 shRNA cells alone were GFP negative (upper panel in column
in vivo), whereas .95% of the cells recovered from the mice injected
with p185wt GFP cells alone were GFP positive (middle panel in
column in vivo). Remarkably, the cells recovered from the mice in-
jected with the mixed cells were mostly, if not all, GFP positive
(Figure 6B, lower panel in column in vivo). However, when grown
in vitro for the same time period, the mixed cells remain at a ratio of
1:1 (Figure 6B, lower panel in column in vitro). These results suggest
that, although there is no growth advantage of p185wt GFP cells over
p185wt Abi1 shRNA cells invitro under the culture condition we used,
p185wt GFP cells exhibited growth advantage over p185wt Abi1
shRNA cells in vivo. Thus, the data support the notion that the knock
down of Abi1 expression impedes in vivo competitive expansion of
the p185wt Abi1 shRNA cells.
Abi1 is required for Bcr-Abl-induced activation of Lyn kinases
Abi1 has been shown to play a role in signal transduction trigged by
growth factors (26,27,32,36). It has been widely accepted that Src
family kinases are critical players that act downstream of growth
factor/cytokine receptors to stimulate cell growth, survival and hom-
ing. To determine the mechanism by which Abi1 contributes to Bcr-
Abl-induced leukemogenesis, we examined the effect of Abi1 knock-
down on activation of Lyn, a member of Src family kinases that is
expressed in hematopoietic cells and required for Bcr-Abl-induced
leukemogenesis (46). Lyn is mostly inactive in starved Ba/F3 cells
but its activity is increased upon IL3 stimulation, as revealed by in-
creased level of phosphorylated tyrosine 416 (Figure 7, compare lane
1 with lane 4). In p185wt-transformed Ba/F3 cells, Lyn is constitu-
tively activated (Figure 7, lanes 2 and 5). Knock down of the Abi1
expression in p185wt cells resulted in a reduction of Lyn activation
(Figure 7, compare lane 3 with lane 2). Moreover, while the IL3 is
a potent stimulator of Lyn activity in Ba/F3 cells, it failed to stimulate
Lyn activation in p185wt Abi1 shRNA cells (Figure 7A, compare lane
6 with lane 3).
Discussion
To examine the role of Abi1 in Bcr-Abl-induced leukemogenesis, we
knocked down its expression in p185wt Ba/F3 cells by shRNA-
mediated gene silencing. The messenger RNA and protein levels of
Abi1 were decreased by at least 90% in p185wt cells transduced with
Abi1 shRNA. In these cells, the expression of Abi2 is also dramati-
cally downregulated due to Bcr-Abl-induced activation of proteolytic
pathways (38). Furthermore, the expression of Abi3 (also known as
new molecule including SH3) in these cells is relatively low as de-
termined by DNA microarray analysis (Weidong Yu and Zonghan
Dai, unpublished data). Thus, the p185wt cells transduced with
Abi1 shRNA may provide a simpliﬁed system for analysis of the role
of Abi pathway in Bcr-Abl-induced leukemogenesis. Knock down of
Abi1 expression did not affect tyrosine kinase activity of Bcr-Abl,
nor did it have any effect on Bcr-Abl-induced IL3-independent
growth in vitro. However, Abi1 knockdown inhibited Bcr-Abl-stim-
ulated actin cytoskeleton remodeling, MT1-MMP clustering as well
as cell adhesion and migration in vitro. More importantly, knock
down of the expression of Abi1 impaired Bcr-Abl-induced leukemo-
genesis in vivo. Remarkably, the mice receiving p185wt Abi1 shRNA
cells did not develop splenomegaly, which is a common pathologic
characteristic of Bcr-Abl-induced leukemogenesis. These results are
consistent with our previous report shown that p185DSH3DC, a mutant
Bcr-Abl defective in signaling to Abi pathway, failed to stimulate cell
migration in vitro and to induce chronic myelogenous leukemia-like
disease in vivo (39). Together, these studies highlight the importance
of Abi1 in Bcr-Abl-induced leukemogenesis.
Abi1 plays a key role in regulation of actin polymerization, a fun-
damental cellular process that controls cell adhesion and motility. In
cultured ﬁbroblast cells and melanoma cells, blockade of Abi1 path-
way abrogated growth factor-stimulated membrane rufﬂing and the
formation of lamellipodia (36,47,48). In p185wt-transformed Ba/F3
cells, Abi1 is tyrosine phosphorylated and translocated to a site adja-
cent to membrane where an F-actin-enriched structure was assembled
(40). More recent studies have shown that this F-actin-enriched struc-
ture shares some similarities with invadopodium, a specialized
Table I. Summary of the disease development in mice injected with p185wt/
BaF3 cells and the p185wt/BaF3 cells expressing Abi1 shRNA
Mouse Latency
a
(days)
Spleen weight
(g)
Liver weight
(g)
Ba/F3 injected
A1 .90
b 0.04 1.18
A2 .90
b 0.05 1.35
A3 .90
b 0.05 1.51
A4 .90
b 0.05 1.36
A5 .90
b 0.06 1.45
A6 .90
b 0.05 1.73
p185wt injected
A1 18 —
c —
c
A2 20 0.16 3.00
A3 20 0.18 2.98
A4 20 0.16 3.39
B1 13 —
c —
c
B2 14 —
c —
c
B3 16 0.21 3.24
B4 16 0.19 2.88
B5 16 0.18 3.29
B6 19 —
c —
c
Abi1 shRNA injected
A1 32 —
c —
c
A2 34 0.03 1.89
A3 37 0.04 1.23
A4 37 0.06 1.15
A5 37 0.05 1.70
A6 37 0.06 1.76
A7 37 0.07 1.63
aLatency is deﬁned as the time after injection that mice died or become
moribund.
bThe mice injected with Ba/F3 cells survived .90 days without any disease
observed.
cThe mice dead prior to the pathology analysis.
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anoma cells (49,50). Like invadopodium, the F-actin-enriched struc-
tures found in p185wt cells are associated with the membrane and
enriched with multiple structural/regulatory proteins involved in the
regulation of actin cytoskeleton assembly, cell adhesion and extracel-
lular matrix degradation (40,41). It is widely believed that invadopo-
dia play a crucial role in tumor cell invasion and migration (50,51).
Knock down of Abi1 in p185wt cells signiﬁcantly inhibited the for-
mation of invadopodia-like structure and clustering of MT1-MMP
(41). Interestingly, the decreased formation of the invadopodia-like
structures as a consequence of Abi1 knockdown correlated with a de-
crease of cell adhesion and migration on ﬁbronectin-coated surfaces.
Given the importance of the cytoskeletal functions and MT1-MMP
activities in control of hematopoietic cell invasion and homing, it is
conceivable that defects in Abi1-mediated cytoskeletal functions and
MT1-MMP clustering in p185wt Abi1 shRNA cells may account in
part for the failure of these cells to develop splenomegaly in the mice.
Although the knock down of Abi1 expression did notaffect the IL3-
independent growth of p185wt cells in vitro, it impeded the in vivo
competitive expansion of these cells. In addition to the regulation of
actin polymerization, Abi1 is also involved in multiple signaling path-
ways important for cell growth. It has been shown that Abi1 is capable
of binding to a variety of signaling molecules involved in control of
cell proliferation, apoptosis and cytoskeletal functions. These include
c-Abl (16), Abl-related gene product (24), epidermal growth factor
receptor pathway substrate 8 (23), cytoskeleton protein spectrin (25),
guanine nucleotide exchange factors Sos (26,27) and Pix (33), adaptor
protein Grb4 (28), membrane metalloproteinase ADAM19 (35), PI3
kinase p85 subunit (36), reduced nicotinamide dinucleotide phosphate
(NADPH) oxidase adapter protein p47 (30), cyclin-dependent kinase
cdc2 (29), p21-activated kinase Pak2 (31,34) and E3 ubiquitin ligase
cbl (32). The ability to interact with multiple signaling molecules
places Abi1 at a position that may link signals from membrane re-
ceptors to intracellular networks. It is likely that the knock down of
Fig. 5. Pathology analysis of the mice injected with Ba/F3 cells, control p185wt cells and p185wt cells transduced with Abi1 shRNA. (A) Spleen weight of mice
injected with Ba/F3 cells (control) and the p185wt cells expressing with (p185wt þ Abi1 shRNA) or without (p185wt) Abi1 shRNA. (B) Histology of spleens and
livers from the mice receiving Ba/F3 cells (control) and the p185wt cells expressing with (p185wt þ Abi1 shRNA) or without (p185wt ctrl) Abi1 shRNA.
Arrowheads indicate the massively expanded p185wt cells.
Fig. 6. Abi1knockdownimpededinvivo competitiveexpansion ofp185wt cells.(A) Expression of Abi1in Ba/F3cells,p185wt cells transducedwithnon-silencing
shRNA (p185wt control) or Abi1 shRNA (p185wt Abi1 Ri), as well as the cells rescued from bone marrow (BM), peripheral blood (PB) and spleen of the diseased
mice injected with p185wt cells transduced with either non-silencing shRNA or Abi1 shRNA. The 100 lg total proteins from these cells were separated by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane and western blotted (WB) with indicated antibodies. Molecular
markers are indicated. The arrow indicates p185Bcr-Abl.( B) In vivo competitive expansion of p185wt GFP cells and p185wt Abi1 shRNA cells. The p185wt cells
were transduced with MSCV-based retroviruses expressing either GFP or Abi1 shRNA. The GFP-positive p185wt cells were sorted by ﬂuorescence-activated cell
sorting to a purity of .95%. The GFP-positive cells then were mixed with p185wt cells expressing Abi1 shRNA at a ratio of 1:1. The mixed cells were either
cultured in vitro for 5 weeks or injected into Balb/c mice (1   106 cells per mouse) through tail vein. The cells derived from p185wt cells were rescued from bone
marrow and peripheral blood (data not shown) of the diseased mice by selection with puromycin. The rescued cells and the cells cultured invitrowere subjected to
ﬂow cytometry analysis.
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p185wt Abi1 shRNA cell disadvantage in an in vivo environment
where the cells are exposed to numerous factors including cytokines,
growth factors and extracellular matrix. Indeed, it has been reported
that in addition to the regulation of cytoskeleton remodeling, the Abi–
WAVE pathway is also involved in T cell receptor-mediated cell pro-
liferation (52). Consistently, we found that at the presence of IL3, the
p185wt Abi1 shRNA cells grew slower in vitro as compared with
control p185wt cells (data not shown). In an effort to determine the
molecular mechanism by which Abi1 contributes to Bcr-Abl-induced
leukemogenesis, we found that the knock down of Abi1 expression
attenuates Bcr-Abl-stimulated activation of Lyn kinases. Given the
importance of Lyn kinases in regulation of hematopoietic cell growth,
survival and homing, our ﬁndings may provide an explanation why
the Abi1 knockdown impeded in vivo expansion of p185wt Abi1
shRNA cells. More importantly, because recent studies suggest that
Lyn kinases may play a keyrole in leukemia development (46,53), our
observation that Abi1 is involved in abnormal activation of Lyn
kinases in Bcr-Abl-positive leukemic cells may provide insight into
the development of novel therapeutic strategies for treatment of hu-
man leukemia.
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